ClinicalTrials.gg
Drug

Pamiparib clinical trials

Also written BGB-290.

studies test it
28
open now
3
in phase 3
2
first study started
2014

How each study uses pamiparib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pamiparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pamiparib
24
PARP Inhibitor BGB-290
4

Development codes

BGB-290
16

Studies by the year they started

28 studies that test it; most in 2022 (10)

Studies that test pamiparib, by start year
YearStudies
20141
20162
20171
20183
20195
20201
20212
202210
20232
20241

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
10
Phase 2
18
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 18

BeiGene (9) · Sun Yat-sen University (3) · Bai-Rong Xia (1) · University of California, San Francisco (1) · Zhejiang Cancer Hospital (1) · BeOne Medicines (1) · Nader Sanai (1) · M.D. Anderson Cancer Center (1)

Often tested with

Tested in the same studies.

Tislelizumab (5) · Surufatinib (2) · Sitravatinib (1) · Hpk1 Inhibitor BGB-15025 (1) · Zanidatamab (1) · Olaparib (1) · Bevacizumab (1) · Albumin-Bound Paclitaxel (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses pamiparib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 28

See all 28 studies that test pamiparib →

Given beside what is tested · 3 — pamiparib is usual care or a partner of the new treatment

Codes

What other systems call pamiparib · ClinicalTrials.gg INT001345

  • MeSH (NLM) C000707927pamiparibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 8375F9S90CPAMIPARIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q125351134pamiparibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C120553PamiparibOne source FDA
  • DrugBank DB14769One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.